{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:36:47Z","timestamp":1793972207081,"version":"4.8.0"},"reference-count":30,"publisher":"American Academy of Pediatrics (AAP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"\n BACKGROUND<\/jats:title>\n Illicitly manufactured fentanyl (IMF) is the predominant opioid in the US drug supply and is a major contributor to morbidity and mortality during pregnancy. While prenatal opioid exposure is an established risk factor for neonatal opioid withdrawal syndrome (NOWS), the differential effects of IMF vs other opioids on outcomes are largely unknown. Therefore, we aimed to evaluate the associations between prenatal IMF exposure and fetal, perinatal, and neonatal health outcomes.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n We conducted a retrospective cohort study of pregnant women with opioid use disorder (OUD) and their infants who were born between January 2024 and December 2024. Maternal and infant participants were stratified into 2 groups based on the opioids, IMF vs medications for OUD (MOUDs), identified on urine drug testing at delivery. Descriptive statistics were used to describe the characteristics of cohort participants, while \u03c72 and t tests were used to evaluate for differences in outcomes between the groups.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n Among 125 infants, 34 were categorized as IMF exposed, and 91 were categorized as MOUD exposed. Fetal growth restriction, preterm birth, and abnormal growth parameters, including low birth weight and very low birth weight, were more frequently identified among IMF- vs MOUD-exposed infants. In addition, IMF-exposed infants were significantly more likely to require neonatal intensive care unit admission, have a longer neonatal hospital length of stay, and require pharmacologic treatment for NOWS.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n Prenatal IMF exposure was associated with significant neonatal morbidity compared with MOUD exposure, highlighting the importance of engagement in maternal substance use treatment during pregnancy to both maternal and neonatal health outcomes.<\/jats:p>\n <\/jats:sec>","DOI":"10.1542\/hpeds.2025-009094","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:02:53Z","timestamp":1784246573000},"page":"767-775","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes Associated With Illicit Fentanyl Exposure During Pregnancy: A Retrospective Cohort Study"],"prefix":"10.1542","volume":"16","author":[{"given":"Kelsey","family":"Sullivan","sequence":"first","affiliation":[{"name":"1Division of Newborn Medicine, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Bangiolo","sequence":"additional","affiliation":[{"name":"1Division of Newborn Medicine, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Kisseih","sequence":"additional","affiliation":[{"name":"1Division of Newborn Medicine, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Ritter","sequence":"additional","affiliation":[{"name":"2Magee-Womens Research Institute, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candace","family":"Drzik","sequence":"additional","affiliation":[{"name":"2Magee-Womens Research Institute, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Patterson","sequence":"additional","affiliation":[{"name":"2Magee-Womens Research Institute, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Meyn","sequence":"additional","affiliation":[{"name":"2Magee-Womens Research Institute, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Hull","sequence":"additional","affiliation":[{"name":"2Magee-Womens Research Institute, Pittsburgh, Pennsylvania"},{"name":"3Department of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gysella","family":"Muniz","sequence":"additional","affiliation":[{"name":"4Division of General Academic Pediatrics, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Krans","sequence":"additional","affiliation":[{"name":"2Magee-Womens Research Institute, Pittsburgh, Pennsylvania"},{"name":"5Department of Obstetrics and Gynecology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"4","key":"2026083119593057200_r1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ajog.2025.01.007","article-title":"Substance use and use disorders during pregnancy and the postpartum period","volume":"232","author":"Habersham","year":"2025","journal-title":"Am J Obstet Gynecol."},{"key":"2026083119593057200_r2","doi-asserted-by":"crossref","first-page":"108236","DOI":"10.1016\/j.drugalcdep.2020.108236","article-title":"Substance use disorders and risk of severe maternal morbidity in the United States","volume":"216","author":"Jarlenski","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"11","key":"2026083119593057200_r3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1542\/pir.2017-0201","article-title":"Effect of maternal substance abuse on the fetus, neonate, and child","volume":"39","author":"Bailey","year":"2018","journal-title":"Pediatr Rev."},{"issue":"21","key":"2026083119593057200_r4","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1001\/jama.2022.17045","article-title":"US trends in drug overdose mortality among pregnant and postpartum persons, 2017\u20132020","volume":"328","author":"Bruzelius","year":"2022","journal-title":"JAMA."},{"key":"2026083119593057200_r5","author":"Department of Justice\/Drug Enforcement Administration"},{"issue":"16","key":"2026083119593057200_r6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.15585\/mmwr.mm7416a2","article-title":"Trends in suspected fentanyl-involved nonfatal overdose emergency department visits, by age group, sex, and race and ethnicity - United States, October 2020-March 2024","volume":"74","author":"Pickens","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"4","key":"2026083119593057200_r7","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr Opin Psychiatry."},{"key":"2026083119593057200_r8","doi-asserted-by":"crossref","DOI":"10.15620\/cdc:129519","volume-title":"Drug Overdose Deaths Involving Xylazine: United States, 2018\u20132021","author":"Spencer","year":"2023"},{"issue":"3","key":"2026083119593057200_r9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/jamapsychiatry.2023.4523","article-title":"Pregnancy and postpartum drug overdose deaths in the US before and during the COVID-19 pandemic","volume":"81","author":"Han","year":"2024","journal-title":"JAMA Psychiatry."},{"issue":"10","key":"2026083119593057200_r10","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/phar.4616","article-title":"Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: a population-based study","volume":"44","author":"Hasan","year":"2024","journal-title":"Pharmacotherapy."},{"issue":"8","key":"2026083119593057200_r11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40264-021-01080-0","article-title":"Association between prenatal opioid exposure and neurodevelopmental outcomes in early childhood: a retrospective cohort study","volume":"44","author":"Wen","year":"2021","journal-title":"Drug Saf."},{"issue":"2","key":"2026083119593057200_r12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/aje\/kwad183","article-title":"Prenatal exposure to opioids and neurodevelopmental disorders in children: a Bayesian mediation analysis","volume":"193","author":"Wang","year":"2024","journal-title":"Am J Epidemiol."},{"issue":"3","key":"2026083119593057200_r13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/pr.2015.95","article-title":"Longitudinal cognitive development of children born to mothers with opioid and polysubstance use","volume":"78","author":"Nygaard","year":"2015","journal-title":"Pediatr Res."},{"key":"2026083119593057200_r14","doi-asserted-by":"crossref","first-page":"107176","DOI":"10.1016\/j.ntt.2023.107176","article-title":"A 12-month follow-up of infant neurodevelopmental outcomes of prenatal opioid exposure and polysubstance use","volume":"97","author":"Bierce","year":"2023","journal-title":"Neurotoxicol Teratol."},{"key":"2026083119593057200_r15","doi-asserted-by":"crossref","first-page":"107000","DOI":"10.1016\/j.ntt.2021.107000","article-title":"Infant neurodevelopmental outcomes of prenatal opioid exposure and polysubstance use","volume":"86","author":"Labella","year":"2021","journal-title":"Neurotoxicol Teratol."},{"issue":"7","key":"2026083119593057200_r16","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/a-2437-0828","article-title":"Illicit fentanyl in the prenatal period: a significant emerging risk for neonatal opioid withdrawal syndrome","volume":"42","author":"Rana","year":"2025","journal-title":"Am J Perinatol."},{"issue":"12","key":"2026083119593057200_r17","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1111\/add.15582","article-title":"Outcomes associated with the use of medications for opioid use disorder during pregnancy","volume":"116","author":"Krans","year":"2021","journal-title":"Addiction."},{"issue":"4.11","key":"2026083119593057200_r18","doi-asserted-by":"crossref","first-page":"e251814","DOI":"10.1001\/jamahealthforum.2025.1814","article-title":"Buprenorphine treatment in pregnancy and maternal-infant outcomes","volume":"6","author":"Krishnapura","year":"2025","journal-title":"JAMA Health Forum."},{"issue":"6","key":"2026083119593057200_r19","doi-asserted-by":"crossref","first-page":"741.e1","DOI":"10.1016\/j.ajog.2022.11.1293","article-title":"Fentanyl in the labor epidural impacts the results of intrapartum and postpartum maternal and neonatal toxicology tests","volume":"228","author":"Siegel","year":"2023","journal-title":"Am J Obstet Gynecol."},{"issue":"1","key":"2026083119593057200_r20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2431-13-59","article-title":"A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants","volume":"13","author":"Fenton","year":"2013","journal-title":"BMC Pediatr."},{"key":"2026083119593057200_r21","doi-asserted-by":"crossref","first-page":"109380","DOI":"10.1016\/j.drugalcdep.2022.109380","article-title":"Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis","volume":"233","author":"Friedman","year":"2022","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"2026083119593057200_r22","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/1556-4029.15375","article-title":"Prevalence of xylazine in overdose cases: an analysis of Miami-Dade County medical examiner case data","volume":"68","author":"Potoukian","year":"2023","journal-title":"J Forensic Sci."},{"key":"2026083119593057200_r23","doi-asserted-by":"crossref","first-page":"110833","DOI":"10.1016\/j.drugalcdep.2023.110833","article-title":"Xylazine-involved fatal overdoses and localized geographic clustering: Cook County, IL, 2019\u20132022","volume":"249","author":"Delcher","year":"2023","journal-title":"Drug Alcohol Depend."},{"issue":"26","key":"2026083119593057200_r24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.15585\/mmwr.mm7226a4","article-title":"Illicitly manufactured fentanyl-involved overdose deaths with detected xylazine - United States, January 2019-June 2022","volume":"72","author":"Kariisa","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"2026083119593057200_r25","volume-title":"Primary Pediatric Care","author":"Finnegan","year":"1992","edition":"2nd ed"},{"issue":"6","key":"2026083119593057200_r26","doi-asserted-by":"crossref","first-page":"e196405","DOI":"10.1001\/jamanetworkopen.2019.6405","article-title":"Prenatal risk factors and perinatal and postnatal outcomes associated with maternal opioid exposure in an urban, low-income, multiethnic US population","volume":"2","author":"Azuine","year":"2019","journal-title":"JAMA Netw Open."},{"issue":"6","key":"2026083119593057200_r27","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/ALN.0000000000000472","article-title":"Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes","volume":"121","author":"Maeda","year":"2014","journal-title":"Anesthesiology."},{"issue":"2","key":"2026083119593057200_r28","doi-asserted-by":"crossref","first-page":"139.e1","DOI":"10.1016\/j.ajog.2010.10.004","article-title":"Methadone and perinatal outcomes: a retrospective cohort study","volume":"204","author":"Cleary","year":"2011","journal-title":"Am J Obstet Gynecol."},{"issue":"4","key":"2026083119593057200_r29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41372-025-02442-7","article-title":"Association between medication for opioid use disorder during pregnancy and neonatal outcomes","volume":"46","author":"Hall","year":"2026","journal-title":"J Perinatol."},{"key":"2026083119593057200_r30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jpeds.2022.11.040","article-title":"Substance exposure and adverse neonatal outcomes: a population-based cohort study","volume":"256","author":"Umer","year":"2023","journal-title":"J Pediatr."}],"container-title":["Hospital Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article-pdf\/16\/9\/767\/1944738\/hosppeds.2025009094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article-pdf\/16\/9\/767\/1944738\/hosppeds.2025009094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:59:43Z","timestamp":1788220783000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article\/16\/9\/767\/208242\/Outcomes-Associated-With-Illicit-Fentanyl-Exposure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,7,17]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/hpeds.2025-009094","relation":{},"ISSN":["2154-1663","2154-1671"],"issn-type":[{"value":"2154-1663","type":"print"},{"value":"2154-1671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}